Genenta Science (NASDAQ:GNTA) Shares Down 0.6% – Here’s Why

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA)’s share price was down 0.6% during mid-day trading on Wednesday . The company traded as low as $1.64 and last traded at $1.64. 61,336 shares were traded during mid-day trading, a decline of 48% from the average session volume of 118,827 shares. The stock had previously closed at $1.65.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Genenta Science from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 10th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Genenta Science Stock Down 3.6%

The company has a 50 day simple moving average of $1.49 and a 200 day simple moving average of $1.11. The company has a debt-to-equity ratio of 0.35, a quick ratio of 14.16 and a current ratio of 14.16.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new stake in Genenta Science during the third quarter worth approximately $41,000. SmartHarvest Portfolios LLC purchased a new position in shares of Genenta Science in the 4th quarter valued at $26,000. Alyeska Investment Group L.P. purchased a new position in shares of Genenta Science in the 4th quarter valued at $328,000. Norges Bank acquired a new position in shares of Genenta Science during the 4th quarter valued at $337,000. Finally, Weiss Asset Management LP purchased a new stake in Genenta Science during the 4th quarter worth $480,000. Hedge funds and other institutional investors own 15.13% of the company’s stock.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.